Answers are grounded in this paper and cite their sources.
Tumors aberrantly express tumor-associated antigens that can be specifically recognized by T-cells, thereby providing a scientific rationale for the design and clinical testing of immunotherapeutic strategies targeting these antigens. Multiple myeloma is a fatal hematologic malignancy. Here, we review techniques to discover new tumor-associated antigens in multiple myeloma and the latest immunotherapeutic strategies employed in this disease.
No takes yet. Share an insight, caveat, or question.
Chiriva‐Internati et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: